VTU Technology and Biomay, based in Vienna, the two leading Austrian biotechnology companies, entered into a licensing agreement for the production of recombinant allergens. VTU Technology, currently offering a very broad and versatile technology platform available for Pichia pastoris protein production. VTU Technology´s Pichia platform - standing out due to its diversity of expression tools and ingenious expression strategies - enables the production of high-performance expression strains, high-quality proteins and economically, viable protein production processes. Biomay, a global leader in allergy immunotherapy, will apply industrial Pichia expression strains generated by VTU for the commercial production of recombinant allergens. As per agreement, VTU Technology will receive royalties based on Biomay´s worldwide sales of the recombinant allergens.
Subscribe to PharmaTutor News Alerts by Email >>
